Twist Bioscience Corp (TWST) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended December 31, 2024 (Q1 of Fiscal Year 2025). Twist Bioscience is a synthetic biology company utilizing silicon-based DNA synthesis technology to manufacture synthetic DNA, RNA, and antibody proteins. The company serves customers in healthcare, industrial chemicals, academic research, and food/agriculture sectors.
Key Financial Metrics
| Metric | Q1 2025 (3 Months Ended Dec 31, 2024) | Q1 2024 (3 Months Ended Dec 31, 2023) |
|---|---|---|
| Revenue | $88.7 million | $71.5 million |
| Gross Profit | $42.8 million | $29.0 million |
| Gross Margin | 48.3% | 40.5% |
| Net Loss | $(31.6) million | $(43.0) million |
| Diluted Net Loss Per Share | $(0.53) | $(0.75) |
| Cash & Cash Equivalents | $221.4 million | $226.3 million (Sep 30, 2024) |
| Short-term Investments | $49.4 million | $50.1 million (Sep 30, 2024) |
| Operating Cash Flow | $(21.4) million | $(23.0) million |
| Accumulated Deficit | $(1,273.5) million | $(1,076.2) million (Dec 31, 2023) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 24% year-over-year, driven primarily by a $9.2 million increase in NGS tools revenue and a $6.8 million increase in synthetic genes revenue.
- Margin Expansion: Gross margin improved by 780 basis points to 48.3%, attributed to higher revenue volumes spreading fixed costs and a reduction in depreciation/amortization expenses due to prior asset impairments.
- Expense Management: Operating loss narrowed by $12.3 million. Research and Development (R&D) expenses decreased 8% due to lower outside service and lab supply costs. Selling, General, and Administrative (SG&A) expenses increased 6% due to higher personnel and third-party service costs.
- Capital Structure: The company recorded a new liability of $15.0 million related to the sale of future revenue (royalty monetization) with XOMA (US) LLC, providing immediate cash liquidity.
Guidance, Outlook, and Risks
- Liquidity: Management expects current cash, cash equivalents, and short-term investments ($270.8 million total) to fund operations for at least one year.
- Strategic Focus: Continued investment in the Wilsonville, Oregon manufacturing facility to increase DNA production and reduce turnaround times. Expansion into biologic drug discovery and digital data storage applications.
- Legal Contingencies: The company is defending a securities class action lawsuit (Peters v. Twist Bioscience Corporation) regarding allegations of false statements about DNA chip technology and accounting practices. A hearing on the motion to dismiss was held in November 2024; the outcome remains uncertain.
- Risk Factors: Key risks include the ability to achieve profitability, competition in the synthetic biology market, intellectual property protection, and the success of new product commercialization.
Investor Verification Checklist
- Verify the sustainability of the 24% revenue growth rate, specifically the contribution from NGS tools and synthetic genes.
- Monitor the status of the Peters v. Twist Bioscience securities class action lawsuit and potential financial impact.
- Assess the burn rate relative to the $270.8 million cash position and the timeline to profitability.
- Review the terms and potential future cash outflows associated with the $15.0 million royalty sale to XOMA.
- Track the utilization and output of the Wilsonville, Oregon manufacturing facility.